MannKind Balance Sheet Health
Financial Health criteria checks 0/6
MannKind has a total shareholder equity of $-230.0M and total debt of $264.1M, which brings its debt-to-equity ratio to -114.9%. Its total assets and total liabilities are $480.9M and $710.8M respectively. MannKind's EBIT is $31.0M making its interest coverage ratio 1.5. It has cash and short-term investments of $307.6M.
Key information
-114.9%
Debt to equity ratio
US$264.15m
Debt
Interest coverage ratio | 1.5x |
Cash | US$307.63m |
Equity | -US$229.97m |
Total liabilities | US$710.85m |
Total assets | US$480.88m |
Recent financial health updates
No updates
Recent updates
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Jul 17MannKind Outperforms As Tyvaso DPI Captures Market Share
May 15This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17MannKind (MNKD) earns $12.5M milestone under licensing deal for treprostinil
Nov 20MannKind: Global Product Sales, Late-Stage Clinical Pipeline Candidate, And Strong Leadership, 34% Upside
Nov 03Financial Position Analysis
Short Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MNKD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MNKD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: MNKD's debt is not well covered by operating cash flow (15%).
Interest Coverage: MNKD's interest payments on its debt are not well covered by EBIT (1.5x coverage).